Current stock page

Financial Data

ABUS Financial Data

Revenue · Earnings · Margins · Balance Sheet · Cash Flow

HealthcareBiotechnologyScore data as of Nov 13, 2026

ABUSArbutus Biopharma Corp

Healthcare / Biotechnology

Leader

Strong Relative Position

BullishEdge 9/10
$4.09+$0.06 (+1.49%)

Latest quote

  • Momentum
    51
  • Value
    92
  • Quality
    82
  • Risk resilience
    62
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Financial Data Overview

Detailed revenue, earnings, margins, balance sheet, cash flow, valuation metrics, technical indicators, and risk measures for deeper research.

Quarterly periods
8
Fundamental metrics
10
Technical indicators
12
Risk measures
6

Quarterly Financial Statements

Updated Nov 16, 2026.

Income statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Revenue$299K$1.01M$179.13M$1.05M$529K$10.74M$1.76M$1.57M
Gross Profit$299K$1.01M$179.12M$1.04M$518K$10.74M-$7.2M-$7.24M
Operating Income-$10.49M-$5.96M$169.12M-$7.64M-$8.29M$1.49M-$34.66M-$13.93M
Net Income$59.12M-$5.14M$169.7M-$3.76M-$7.74M$2.52M-$24.53M-$12.53M
EPS$0.3-$0.03$0.88-$0.02-$0.04$0.01-$0.13-$0.07
Cash flow statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Operating Cash Flow$239.81M-$6.02M-$8.11M-$4.68M-$5.82M-$15.75M-$13.39M-$10.32M
Capital Expenditure$0$0$0$0$0$0$0-$86K
Free Cash Flow$239.81M-$6.02M-$8.11M-$4.68M-$5.82M-$15.75M-$13.39M-$10.4M
Net Cash Provided By Operating Activities$239.81M-$6.02M-$8.11M-$4.68M-$5.82M-$15.75M-$13.39M-$10.32M
Balance sheet
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Total Assets$339.7M$274.03M$277.16M$94.62M$97.71M$103.27M$117.01M$131.71M
Total Debt$328K$3.63M$3.91M$4.19M$4.61M$5M$5.6M$6.12M
Cash And Cash Equivalents$264.19M$19.17M$23.71M$18.01M$22.41M$37.41M$37.08M$36.33M
Total Liabilities$253.95M$15.29M$16.99M$18.04M$20.31M$20.29M$37.85M$34.34M
Total Stockholders Equity$85.75M$258.73M$260.18M$76.58M$77.4M$82.98M$79.16M$97.37M
Key financial metrics
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio3.525.925.24—————
P/B ratio9.033.53.2311.0611.38.057.616.38
P/S ratio4.48———————
Debt To Equity00.010.020.050.060.060.070.06
Free Cash Flow Yield28.53%-2.72%-4.08%-4.68%-5.19%-9.03%-9.80%-10.47%
Financial ratios
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio3.525.925.24—————
P/B ratio9.033.53.2311.0611.38.057.616.38
P/S ratio4.48———————
Return On Equity256.47%59.16%61.77%-43.75%-54.62%-65.38%-96.73%-71.81%
Debt To Equity00.010.020.050.060.060.070.06

Current Stock Metrics

Current fundamental, technical, and risk readings in one place.

Fundamental metrics
MetricValue
Pe3.62x
Pb9.48x
Revenue Growth Yoy-43.48%
EPS Growth Yoy850.00%
Gross Margin99.99%
Operating Margin79.90%
ROE129.13%
ROIC147.83%
Debt To Equity0
FCF Yield27.28%

As of Nov 13, 2026

Technical indicators
MetricValue
Close$4.09
Volume3.31M
RSI (14)48.5
MACD-0.15
MACD signal-0.17
MACD histogram0.02
ADX (14)29.2
SMA (50)$4.46
SMA (200)$4.48
ATR (14)$0.19
Historical volatility (annualized)52.08%
Volume (20-day average)2.44M

As of Nov 13, 2026

Risk measures
MetricValue
Resilience score62/100
Beta1.19
Annual volatility45.89%
Max Drawdown-29.98%
Sharpe Ratio-0.09
VaR (95%, 1-day)-4.39%

As of Nov 13, 2026

Detailed Metrics

Additional measures remain available here while the decision pages stay focused.

Additional fundamental metrics

No additional fundamental metrics are available.

Additional technical indicators

No additional technical indicators are available.

Additional risk measures

No additional risk measures are available.

ABUS Financial Data FAQ

What is Arbutus Biopharma Corp's revenue?

Arbutus Biopharma Corp's revenue is one of the core financial data points for ABUS. Use it with revenue growth, margins, and EPS to understand whether sales are translating into earnings power.

Is Arbutus Biopharma Corp's revenue growing?

Revenue growth shows whether Arbutus Biopharma Corp is expanding from prior periods. Compare growth with margins and free cash flow because faster sales growth is more valuable when profitability holds up.

What is ABUS's EPS?

ABUS's EPS, or earnings per share, helps connect net income to each share. EPS should be compared with EPS growth, P/E ratio, and analyst expectations.

What is Arbutus Biopharma Corp's net income?

Arbutus Biopharma Corp's net income shows profit after costs, taxes, and other expenses. It should be read with revenue, operating margin, EPS, and free cash flow.

How much free cash flow does Arbutus Biopharma Corp generate?

Free cash flow shows how much cash Arbutus Biopharma Corp generates after capital spending. It is useful for judging reinvestment capacity, buybacks, debt reduction, and valuation support.

How much cash and debt does Arbutus Biopharma Corp have?

Cash and debt help frame ABUS's balance-sheet flexibility. Compare liquidity and leverage with free cash flow and profitability before judging financial strength.